Drug Discovery Highlights of 2018: Innovative Technologies & Novel Approaches
SelectScience reflects on the biggest and best drug discovery stories of the year
SelectScience reflects on the biggest and best drug discovery stories of the year
A mass spec scientist, from a world-renowned clinical pathology laboratory, shares the secrets to their success in this exclusive SelectScience interview
Samples from those who had COVID-19 could reveal true infection rate, lethality and vaccines
AEOL 10150 is currently the only drug being developed by BARDA to address the delayed effects of radiation exposure
Thermo Fisher Scientific’s Director of Global Research discusses the use of mass spectrometry at the Hong Kong Jockey Club
The challenges and hurdles of integrating MALDI-TOF, and its impact on patient care
Distinguished speaker Dr. Bruce Levine addresses some of the current healthcare challenges that impact the development of new therapies
In an era where algorithmic hypothesis generation outpaces experimental validation capacity, the Centre of Excellence positions Arctoris at the critical interface between computational design and empirical truth
The certification includes conformity assessment for near-patient testing, enabling its use outside traditional laboratories, directly at the point of care
Three therapeutic targets selected across high‑value clinical indications pipeline planned for four radiotherapy assets with in vivo data expected by end of 2026
Michael Richardson explains how Inotiv is unlocking new insights into disease mechanisms and therapeutic effectiveness using spatial transcriptomics, proteomics, and AI-powered image analytics.